The content on this site is intended for healthcare professionals only
Dr Sujit Nair speaks to ecancer about a trial investigating neoadjuvant poly-ICLC for prostate cancer.
Poly-ICLC is a double-stranded RNA that mimics viral activity, thereby stimulating the immune response.
The trial used a dose escalation strategy in 12 patients diagnosed with clinically localised prostate cancer with plans for surgery.
The trial demonstrates the feasibility of intratumoral immunotherapy for prostate cancer using the investigational agent poly-ICLC.
Treatment with poly-ICLC reliably transforms the cold microenvironment of prostate cancer into a hot, immune-enhanced ecosystem.
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective perioperative strategy for MIBC
EAU 2024: Bladder cancer latest
Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC
mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity
Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity
